NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its quarterly earnings data on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.53) by $0.12. The medical instruments supplier earned $0.60 million during the quarter, compared to analyst estimates of $0.54 million. View TransEnterix's earnings history.

1 equities research analysts have issued 1 year target prices for TransEnterix's shares. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's stock price to reach $1.00 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View analysts' price targets for TransEnterix.

News headlines about TRXC stock have been trending negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutTransEnterix.

TransEnterix saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 3,150,000 shares, a decrease of 6.3% from the April 15th total of 3,360,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the short-interest ratio is presently 1.8 days. Approximately 9.8% of the company's shares are short sold. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Relevium Technologies (RLV), Akers Biosciences (AKR), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY), Commerzbank (CZMWY) and CONVATEC GRP PL/ADR (CNVVY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix's stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (3.72%), BlackRock Inc. (2.51%), First Trust Advisors LP (1.31%), Russell Investments Group Ltd. (0.89%), State Street Corp (0.60%) and Perkins Capital Management Inc. (0.49%). Company insiders that own TransEnterix stock include Andrea Biffi, Joseph P Slattery, Todd Pope, William N Starling Jr and William N Starling, Jr. View institutional ownership trends for TransEnterix.

TRXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Morgan Stanley. View insider buying and selling activity for TransEnterix.

TRXC stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, Russell Investments Group Ltd., State Street Corp, Perkins Capital Management Inc., BlackRock Inc., Invesco Ltd., Two Sigma Investments LP, and First Trust Advisors LP. View insider buying and selling activity for TransEnterix.

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.61.

TransEnterix has a market capitalization of $31.44 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.